Published in Cancer Res on July 01, 2002
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev (2010) 4.75
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer (2003) 2.08
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem (2008) 1.87
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling. Nucleic Acids Res (2006) 1.74
Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency. Cytotherapy (2011) 1.73
RNA amplification for successful gene profiling analysis. J Transl Med (2005) 1.55
An immunologic portrait of cancer. J Transl Med (2011) 1.50
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res (2008) 1.38
Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics (2009) 1.34
Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med (2008) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med (2006) 1.21
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med (2011) 1.15
Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines (2010) 1.15
A gene expression signature associated with survival in metastatic melanoma. J Transl Med (2006) 1.13
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res (2011) 1.10
Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med (2010) 1.06
The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother (2009) 1.06
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer (2013) 1.06
Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med (2012) 1.04
Melanoma-restricted genes. J Transl Med (2004) 1.03
Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother (2009) 1.01
Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. J Transl Med (2009) 1.00
Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med (2005) 0.98
Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med (2010) 0.96
A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res (2010) 0.93
Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med (2005) 0.92
Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics (2008) 0.92
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92
IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes. Br J Cancer (2013) 0.89
A genetic inference on cancer immune responsiveness. Oncoimmunology (2012) 0.86
Changing paradigm through a genome-based approach to clinical and basic immunology. J Transl Med (2004) 0.86
Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. Sci Rep (2016) 0.85
Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells. Transfusion (2008) 0.85
Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. OMICS (2011) 0.83
Understanding the response to immunotherapy in humans. Springer Semin Immunopathol (2005) 0.83
Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett (2009) 0.83
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med (2014) 0.82
CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res Treat (2010) 0.82
New take on comparative immunology: relevance to immunotherapy. Immunotherapy (2009) 0.82
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80
Development and validation of predictive indices for a continuous outcome using gene expression profiles. Cancer Inform (2010) 0.80
Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers. Cancers (Basel) (2014) 0.80
Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma. PLoS One (2013) 0.80
T-cell intracellular antigens function as tumor suppressor genes. Cell Death Dis (2015) 0.79
DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. Ann Surg (2005) 0.79
Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessment. J Mol Diagn (2010) 0.79
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Adv Cancer Res (2015) 0.78
A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles. J Cancer Res Clin Oncol (2006) 0.78
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017) 0.77
Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. Oncoimmunology (2016) 0.77
Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunol Immunother (2012) 0.76
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunol Res (2016) 0.76
The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. Ann Transl Med (2016) 0.75
Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. Oncoimmunology (2017) 0.75
Assessment of fine needle aspiration feasibility and specimen adequacy for molecular diagnostics of benign vocal fold lesions. Laryngoscope (2013) 0.75
Turning laboratory findings into therapy: a marathon goal that has to be reached. Pol Arch Med Wewn (2009) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
High-fidelity mRNA amplification for gene profiling. Nat Biotechnol (2000) 6.97
A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell (1991) 5.65
Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature (1996) 5.30
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res (1998) 4.68
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23
Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A (1997) 2.02
Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. Blood (2000) 1.62
Cytokines and Immune Response in the Tumor Microenvironment. J Immunother (1991) (2001) 1.59
A natural history of melanoma: serial gene expression analysis. Immunol Today (2000) 1.08
A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol Cell Biochem (1999) 1.08
Transcription factors IRF-1 and IRF-2: linking the immune responses and tumor suppression. J Cell Physiol (1997) 0.99
Diagnostic lessons of mucosal melanoma with osteocartilaginous differentiation. Histopathology (1998) 0.97
Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia. Leukemia (1997) 0.96
Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. Antimicrob Agents Chemother (2000) 0.89
The interferon-alpha regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors. Ann Oncol (2000) 0.85
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
International network of cancer genome projects. Nature (2010) 20.35
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
Multiple-laboratory comparison of microarray platforms. Nat Methods (2005) 11.74
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Mapping human genetic diversity in Asia. Science (2009) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Prediction error estimation: a comparison of resampling methods. Bioinformatics (2005) 6.41
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Analysis of gene expression data using BRB-ArrayTools. Cancer Inform (2007) 6.09
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet (2003) 5.99
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol (2006) 4.93
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60